A Study of LY3375880 in Healthy Participants



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 65
Updated:12/12/2018
Start Date:November 17, 2017
End Date:November 16, 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3375880 in Healthy Subjects

The purpose of this study is to evaluate how well LY3375880 (study drug) is tolerated in
healthy participants and what side effects may occur. The study drug will be administered
either subcutaneously (SC) under the skin or intravenously (IV) into a vein in the arm.

This is a two-part study. Participants will enroll in only one part. Part one will last about
16 weeks including screening and follow-up. This part will include 2 nights at the study
site. Part two will last about 20 weeks including screening and follow-up. This part will
include 2 nights at the study site for each dose.


Inclusion Criteria:

- Are overtly healthy males or females, as determined by medical history and physical
examination

- Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²) inclusive

- Are reliable and willing to make themselves available for the duration of the study
and are willing to follow study procedures

Exclusion Criteria:

- Have known allergies to LY3375880, related compounds or any components of the
formulation, or history of significant atopy

- Are women who are of childbearing potential or who are lactating
We found this trial at
1
site
Parexel Early Phase Unit at Glendale
Glendale, California 91206
Principal Investigator: Hakop Gevorkyan, MD
Phone: 818-254-1624
?
mi
from
Glendale, CA
Click here to add this to my saved trials